Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/Ib Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer

Next Previous
Trial Profile

Phase I/Ib Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Ipatasertib (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions

Most Recent Events

  • 29 May 2024 Trial design stating Enrollment is currently at dose level 2 in the escalation phase, and is expected to complete accrual in 2025 is discussed in an abstract published at 60th Annual Meeting of the American Society of Clinical Oncology
  • 23 May 2024 According to a Rutgers Cancer Institute of New Jersey media release, updates from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago (and online) from May 30-June 4.
  • 05 Dec 2023 Number of treatment arms are increased from 1 to 2 by the addition of Experimental: Dose Escalation (ipatasertib, cisplatin, radiation therapy) arm. Study design changed from Single Group Assignment to sequential.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top